dabigatran dose 2

DRUG2 trials

Conditions

Atrial FibrillationStroke

Phase 3

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate

Boehringer IngelheimAtrial Fibrillation, Stroke

Start: 2005-12-31Updated: 2019-04-17

RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial

CompletedNCT00808067

Boehringer IngelheimAtrial Fibrillation

Start: 2008-11-30End: 2012-12-31Updated: 2014-06-09

American Heart Journal2023-03-2711 citations

Impact of a Patient’s Baseline Risk on the Relative Benefit and Harm of a Preventive Treatment Strategy: Applying Trial Results in Clinical Decision Making

Journal of the American Heart Association2021-12-225 citations

Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: A secondary analysis of the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) trial

PLoS ONE2021-08-195 citations

Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation

Cardiovascular Research2021-08-0445 citations

Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas

Open Heart2021-03-0111 citations

Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation

Journal of the American Heart Association2020-12-0964 citations

Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial

European Heart Journal2020-03-2331 citations

Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation

Circulation2019-05-0316 citations

Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation.

2018-07-0951 citations

Measuring the Anticoagulation Effects of Exosite I Thrombin Inhibitors: Utility and Limitations of Clotting Assays, Thromboelastography, and Calibrated Automated Thrombography

Blood2017-12-07

A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score

European Heart Journal2017-09-27120 citations

Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation— the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study

EP Europace2017-05-1719 citations

Effects of dabigatran according to age in atrial fibrillation

Heart2017-02-1788 citations

A Prospective, Randomized, Open-Label Study to Evaluate Two Management Strategies for Gastrointestinal Symptoms in Patients Newly on Treatment with Dabigatran.

2016-10-058 citations

Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation

Circulation2016-08-29102 citations

Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease

Circulation2016-08-06164 citations

The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.

2016-04-04340 citations

D-dimer and factor VIIa in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy

Thrombosis and Haemostasis2016-01-0125 citations

Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial.

2015-06-01148 citations

Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial.

2015-05-2851 citations

20 more papers not shown

dabigatran dose 2

Sponsors

Conditions

Phase 3

Related Papers